Loading...
01/10 16:15
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several concerns: flat or declining revenues in key segments, tariff impacts, deferred spending, and lack of detailed guidance. While management projects some positive future trends, uncertainties around tariffs, government spending, and healthcare policies persist. The Q&A section highlights analysts' concerns over deferred projects and lack of clarity in management's responses. Despite some positive aspects, such as share repurchases and potential EPS growth in Q4, the overall sentiment is negative due to current financial weaknesses and uncertainties.
Adjusted EPS $0.90 at the high end of guidance range with 8% growth in trailing 12 months adjusted free cash flow. Reasons for change include successful spin-off of Ralliant and resilience in continuing operations despite customer demand pressures.
Adjusted EPS (Continuing Operations) $0.58 with 14% growth in trailing 12 months free cash flow. Reasons for change include customer demand pressures from tariff uncertainty, constrained government spending, and evolving healthcare policy dynamics.
Total Revenue Just over $1 billion, down 0.4% year-over-year. Core revenue declined 0.7%. Reasons for decline include customer demand responses to macro pressures and uncertainty, particularly in the last few weeks of June.
Adjusted Gross Profit $650 million, similar to last year. Adjusted gross margins were flat year-over-year due to pricing actions, growth in higher-margin recurring revenues, and lower costs from supply chain countermeasures offset by tariff-related cost pressures.
Adjusted EBITDA $288 million, in line with Q2 of last year. Adjusted EBITDA margins held steady year-over-year. Reasons include stable adjusted gross profit and lower interest expense on lower debt balances.
Free Cash Flow $180 million in Q2 with trailing 12-month free cash flow of $939 million, representing a 14% year-over-year increase. Reasons include strong cash generation and operational efficiency.
Intelligent Operating Solutions Revenue Flat year-over-year. Reasons for flat growth include tariff uncertainty, deferred customer spending, and constrained U.S. government spending.
Advanced Healthcare Solutions Revenue $320 million, down 1.3% year-over-year. Core revenue declined 1.9%. Reasons for decline include reimbursement policy changes and deferral of U.S.-based hospital capital expenditures.
Fluke's 1670 Series Multifunction Installation Tester: Named most valuable product in Control Engineering's 2025 Product of the Year Awards.
Gordian's cloud-based assessment and capital planning module: Strong adoption driving double-digit orders growth.
Provation's AI assistants: Launched intelligent automation to drive productivity in key health care workflows.
Latin America growth strategy: Delivered double-digit Q2 growth in the IOS segment in the region.
Fluke's high-growth applications: Achieved high single-digit growth in distributed energy and data centers.
Recurring revenue at Fluke: Achieved double-digit ARR growth in the quarter.
AI-enabled customer experience improvements: Implemented across portfolio to enhance net dollar retention and customer lifetime value.
President's Kaizen Week: Nearly 1,000 team members participated, focusing on growth opportunities and AI capabilities.
Spin-off of Ralliant: Completed ahead of schedule, simplifying Fortive's operations and focus.
Fortive Accelerated strategy: Introduced to drive faster profitable growth and shareholder value creation.
Disciplined capital allocation: Focused on organic growth, bolt-on M&A, share repurchases, and growing dividends.
Customer demand pressures: Customer demand pressures in the second half of June were caused by tariff uncertainty, constrained government spending, and evolving healthcare policy dynamics, which negatively impacted revenue growth.
Tariff-related cost pressures: Tariff-related cost pressures created a $0.02 headwind to EPS in Q2 and are expected to have a gross impact of $40 million to $55 million in the second half of 2025, with potential revenue visibility challenges.
Government spending constraints: Constrained U.S. government spending and fiscal tightening at state and local levels pressured revenue in certain segments, particularly Gordian, which saw reduced procurement revenue.
Healthcare policy changes: Uncertainty around healthcare reimbursement policies led to deferral of U.S.-based hospital capital expenditures on healthcare equipment, impacting revenue in the Advanced Healthcare Solutions segment.
Revenue volatility: Revenue growth turned negative in the last few weeks of Q2 due to macroeconomic pressures, resulting in a $30 million shortfall against expectations.
Global trade environment: Volatility in the global trade environment, particularly U.S.-China tariffs, is creating challenges for revenue visibility and near-term revenue impacts.
Full Year Adjusted EPS Guidance: Fortive is initiating full year adjusted EPS guidance for new Fortive at $2.50 to $2.60 per share. This outlook assumes a continuation of the market dynamics experienced in Q2 and reflects the expected net impact of tariffs based on currently announced rates.
Revenue Growth Expectations: Second half core revenue growth is expected to be broadly in the range of the core growth seen in the first half of the year. Q3 reported revenue is expected to be broadly similar to Q2, including a modest tailwind from FX.
Segment-Specific Revenue Projections: Advanced Healthcare Solutions (AHS) core growth in the second half is expected to be similar to Q2, with a more challenging year-over-year comparable in Q3.
Adjusted EBITDA and EPS Phasing: Q3 adjusted EBITDA is expected to be lower than Q2 on a dollar basis due to typical seasonality. Q4 adjusted EPS is expected to be meaningfully higher than Q3, which is currently expected to be slightly lower than Q2 on a cents basis.
Tariff Impact Mitigation: Gross tariffs are expected to be mitigated fully by the fourth quarter, with a modest gross margin and EPS headwind in Q3 as countermeasures continue to phase in.
Capital Allocation Plans: Fortive plans to use the remaining dividend proceeds from the Ralliant spin-off for share repurchases. The company is also activating its bolt-on M&A engine to pursue accretive opportunities aimed at enhancing shareholder returns.
Medium-Term Financial Framework: The medium-term financial framework shared at the recent Investor Day remains intact, with a focus on accelerated growth and shareholder value creation in the coming years.
Dividend Policy: Fortive plans to maintain a growing dividend as part of its capital allocation priorities.
Share Repurchase Program: Fortive deployed approximately $140 million towards share repurchases during Q2 2025. From the time of the spin-off announcement in September 2024 through June 2025, over 75% of consolidated free cash flow was allocated to share repurchases. Additionally, Fortive plans to use remaining proceeds from the Ralliant spin-off dividend for further share repurchases.
The earnings call highlights strong financial performance with positive EPS guidance, revenue growth, and strategic share repurchases. The Q&A session reinforces confidence with recurring revenue growth and regional demand trends. Despite some uncertainties in guidance details, the overall sentiment is positive, supported by strategic focus on M&A and shareholder returns.
The earnings call reveals several concerns: flat or declining revenues in key segments, tariff impacts, deferred spending, and lack of detailed guidance. While management projects some positive future trends, uncertainties around tariffs, government spending, and healthcare policies persist. The Q&A section highlights analysts' concerns over deferred projects and lack of clarity in management's responses. Despite some positive aspects, such as share repurchases and potential EPS growth in Q4, the overall sentiment is negative due to current financial weaknesses and uncertainties.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
